Insurance Pharmaceutical Companies White Paper 
pharmaphorum
JUNE 12, 2025
Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
Pharmaceutical Technology
JUNE 6, 2025
In one of the fierier remarks from the roundtable, RFK Jr said: “At every level, doctors, other providers, our hospitals, the pharmaceutical companies, the insurance companies, all make money by keeping us sick. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 19, 2025
Large pharmaceutical companies such as AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications, accounting for 63% of licensing deals between 2021 and 2025 year-to-date. ASOs accounted for more than half ($3.54 billion), while siRNAs made up more than a third ($2.51
Pharmaceutical Technology
JUNE 25, 2025
By GlobalData Learn more about Strategic Intelligence In light of the approvals of Leqembi and Kisunla, large pharmaceutical companies are increasingly investing in Alzheimer’s disease through high-value acquisitions. Stay proactive with real-time data and expert analysis.
Pharmaceutical Technology
JUNE 25, 2025
Other countries from outside the EU and international organisations such as pharmaceutical companies will be able to apply to join HealthData@EU for secondary use in March 2034. In March 2031, secondary use data will be made available, including medical images, lab results, and hospital discharge reports.
Pharmaceutical Technology
JUNE 25, 2025
Vaccine R&D stagnation likely Although ACIP recommendations are separate from the US Food and Drug Administration (FDA)’s approvals, national immunisation recommendation provides a key pillar on which to guide pipeline development for a pharmaceutical company. Give your business an edge with our leading industry insights.
Pharmaceutical Technology
FEBRUARY 7, 2023
Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. In Europe, the pricing and reimbursement (P&R) of pharmaceuticals is governed by individual member states.
Expert insights. Personalized for you.
59 
Let's personalize your content